213 related articles for article (PubMed ID: 12411093)
1. [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Jiang L; Zhao N; Ni L
Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Jun; 23(3):213-7. PubMed ID: 12411093
[TBL] [Abstract][Full Text] [Related]
2. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.
Islam MN; Alam MN; Haq SA; Moyenuzzaman M; Patwary MI; Rahman MH
Bangladesh Med Res Counc Bull; 2000 Apr; 26(1):1-7. PubMed ID: 11192489
[TBL] [Abstract][Full Text] [Related]
4. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
5. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
6. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
Ideguchi H; Ohno S; Ishigatsubo Y
J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
[TBL] [Abstract][Full Text] [Related]
7. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
Papadopoulos NG; Alamanos Y; Papadopoulos IA; Tsifetaki N; Voulgari PV; Drosos AA
J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
[TBL] [Abstract][Full Text] [Related]
8. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
Taniguchi A; Urano W; Tanaka E; Furihata S; Kamitsuji S; Inoue E; Yamanaka M; Yamanaka H; Kamatani N
Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
[TBL] [Abstract][Full Text] [Related]
10. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis.
McKendry RJ; Dale P
J Rheumatol; 1993 Nov; 20(11):1850-6. PubMed ID: 8308769
[TBL] [Abstract][Full Text] [Related]
11. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
[TBL] [Abstract][Full Text] [Related]
12. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
O'Dell JR; Petersen K; Leff R; Palmer W; Schned E; Blakely K; Haire C; Fernandez A
J Rheumatol; 2006 Feb; 33(2):213-8. PubMed ID: 16358366
[TBL] [Abstract][Full Text] [Related]
13. The safety and effectiveness of a chloroform/methanol extract of Tripterygium wilfordii Hook F (T2) plus methotrexate in treating rheumatoid arthritis.
Zhang W; Shi Q; Zhao LD; Li Y; Tang FL; Zhang FC; Zhang X
J Clin Rheumatol; 2010 Dec; 16(8):375-8. PubMed ID: 21085018
[TBL] [Abstract][Full Text] [Related]
14. Adverse events in methotrexate-treated rheumatoid arthritis patients.
Sandoval DM; Alarcón GS; Morgan SL
Br J Rheumatol; 1995 Nov; 34 Suppl 2():49-56. PubMed ID: 8535650
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
16. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
O'Dell JR
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
Aletaha D; Smolen JS
J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
[TBL] [Abstract][Full Text] [Related]
18. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis.
Galindo-Rodriguez G; Avina-Zubieta JA; Fitzgerald A; LeClerq SA; Russell AS; Suarez-Almazor ME
J Rheumatol; 1997 Apr; 24(4):633-8. PubMed ID: 9101493
[TBL] [Abstract][Full Text] [Related]
19. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
Helliwell PS; Taylor WJ;
J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
[TBL] [Abstract][Full Text] [Related]
20. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
